Refining letermovir prophylaxis strategies and CD4 + T cell-guided discontinuation in aplastic anemia patients post-allogeneic HSCT: a retrospective analysis. (PubMed, Eur J Med Res) - Jan 20, 2026 - "Letermovir prophylaxis significantly reduces the incidence of CMV infection in AA patients post-allo-HSCT. Discontinuing letermovir based on CD4 + T cells appears to be an effective strategy for minimizing both early and late CMV infections, indicating that immune recovery markers can guide safer and more personalized prophylaxis durations. Further studies are necessary to confirm these findings and refine the criteria for stopping letermovir prophylaxis."
Journal • Retrospective data • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation • CD4
|
|
Caixia Wang; Fangfang Yang; Liangliang Wu; Ming Zhou; Qi Xiang; Ruiqing Zhou; Shilin Xu; Shiyi Pan; Shunqing Wang; Tingfen Deng; Wei Zhou; Wenjian Mo; Xiaoqing He; Xiaowei Chen; Yuling Zhang; Yumiao Li; Yuping Zhang
|